imiquimod has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jun, L; Kun, X; Lu, L; Pin, C; Wei, C; Xiangjin, X; Xiaohong, L; Xin, L; Yunjie, Y; Zhenting, Z | 1 |
| Chen, P; Li, X; Shao, Z; Xu, X | 1 |
2 other study(ies) available for imiquimod and Alloxan Diabetes
| Article | Year |
|---|---|
Activation of the STING-IRF3 pathway involved in psoriasis with diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Humans; Imiquimod; Interferon Regulatory Factor-3; Mice; Psoriasis | 2022 |
DPP-4 inhibitor linagliptin ameliorates imiquimod-induced psoriasis-like skin alterations in type 2 diabetic mice by inhibiting the MAPK/NF-κB inflammatory pathway.
Topics: Animals; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Imiquimod; Insulin Resistance; Interleukin-23; Linagliptin; Mice; NF-kappa B; Psoriasis; Tumor Necrosis Factor-alpha | 2022 |